New drug Noscapine

Cougar Biotechnology, Inc., a privately held biotechnology company, today announced the presentation of results from preclinical experiments that demonstrate the effectiveness of the Company's drug CB3304 (noscapine) for the treatment of non-Hodgkin's lymphoma and multiple myeloma. The data was presented as a poster presentation at the American Society of Hematology Annual Meeting.

The preclinical studies demonstrate that noscapine exhibits potent antitumor activity against non-Hodgkin's lymphoma and myeloma in vitro as well as in vivo in xenograft models. In vivo studies demonstrated that in xenograft models, daily administration of noscapine resulted in tumor growth delays of between 30-80% of the control tumor volumes.

Owen O'Connor, MD, PhD, from Memorial Sloan Kettering Cancer Center stated "Noscapine exhibited marked activity in non-Hodgkin's lymphoma and multiple myeloma cell lines that appears to complement the activity of conventional cytotoxic therapies. As noscapine may represent a new, well-tolerated, oral therapy for the treatment of lymphoma and myeloma, further clinical studies with the drug are warranted."